Best Available Therapy

DRUG11 trials

Sponsors

Pfizer, CTI BioPharma, Novartis Pharmaceuticals, Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.), Shionogi

Conditions

Abdominal InfectionAcute PyelonephritisBacteremiaBloodstream InfectionsBloodstream Infections (BSI)COVID-19Carbapenem-Resistant Enterobacteriaceae InfectionComplicated Intra-abdominal Infection

Phase 2

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

CompletedNCT03869437

The University of QueenslandBloodstream Infections

Start: 2019-10-28End: 2024-01-29Updated: 2024-02-13

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

CompletedNCT04358783

Hospital Universitario Dr. Jose E. GonzalezCoronavirus Infection

Start: 2020-04-27End: 2021-05-01Updated: 2021-05-26

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

TerminatedNCT04854096

NS Pharma, Inc.Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis

Start: 2023-01-31End: 2024-05-16Updated: 2025-05-23

Phase 3

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

CompletedNCT01644643

PfizerComplicated Urinary Tract Infection, Complicated Intra-abdominal Infection

Start: 2013-01-31End: 2014-09-30Updated: 2017-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

TerminatedNCT01773187

CTI BioPharmaPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

Start: 2013-01-31End: 2016-04-30Updated: 2020-09-29

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

CompletedNCT02038036

Novartis PharmaceuticalsPolycythemia Vera

Start: 2014-03-25End: 2020-04-07Updated: 2021-07-20

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

TerminatedNCT02055781

CTI BioPharmaPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

Start: 2014-02-28End: 2016-04-30Updated: 2021-11-18

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

CompletedNCT02168946

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia +3

Start: 2014-07-31End: 2017-07-21Updated: 2019-03-04

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

CompletedNCT02714595

ShionogiHealthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP) +3

Start: 2016-09-07End: 2019-04-22Updated: 2021-01-12

Unknown Phase

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

CompletedNCT04167228

Maimónides Biomedical Research Institute of CórdobaCarbapenem-Resistant Enterobacteriaceae Infection

Start: 2019-10-01End: 2021-05-05Updated: 2021-07-20

Calcifediol in the Treatment of COVID 19

CompletedNCT05819918

Maimónides Biomedical Research Institute of CórdobaCOVID-19

Start: 2022-04-01End: 2023-04-17Updated: 2023-04-28

Related Papers

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Figshare2026-07-01

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Figshare2026-06-19

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Figshare2026-06-19

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Expert Review of Hematology2026-06-18

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Blood2025-11-03

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.

2025-10-061 citations

ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis

Nutrients2025-06-10

Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial.

Journal of Clinical Oncology2025-05-28

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Blood2024-11-05

Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: <scp>PERSIST</scp>‐2 Landmark Analysis of Survival

European Journal Of Haematology2024-10-145 citations

Latent Class Analysis Reveals, in patient profiles, COVID-19-related better prognosis by calcifediol treatment than glucocorticoids.

2024-08-311 citations

Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.

Journal of Clinical Oncology2024-06-011 citations

Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.

Journal of Clinical Oncology2024-06-01

Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme

Journal of Antimicrobial Chemotherapy2023-09-1316 citations

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Blood Advances2023-08-027 citations

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

HemaSphere2023-08-01

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.

Journal of Clinical Oncology2023-06-012 citations

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.

Journal of Clinical Oncology2023-06-01

Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden

Blood2022-11-15

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).

Journal of Clinical Oncology2022-06-015 citations

37 more papers not shown